JP2024531900A - 新規の抗ｓｉｒｐａ抗体 - Google Patents

新規の抗ｓｉｒｐａ抗体 Download PDF

Info

Publication number
JP2024531900A
JP2024531900A JP2024505469A JP2024505469A JP2024531900A JP 2024531900 A JP2024531900 A JP 2024531900A JP 2024505469 A JP2024505469 A JP 2024505469A JP 2024505469 A JP2024505469 A JP 2024505469A JP 2024531900 A JP2024531900 A JP 2024531900A
Authority
JP
Japan
Prior art keywords
seq
sequence
antibody
cancer
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024531900A5 (enExample
Inventor
ルー，ホンタオ
ニウ，シャオフェン
ワン，フェンリー
ワン，チュンニェン
チャオ，ジンフェン
シン，ロウメイ
ワン，ハイイン
ユー，ジンフェン
リー，レイ
ウー，ジーハオ
ガオ，ルイ
チウ，ヤンシェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elpiscience Biopharma Ltd
Original Assignee
Elpiscience Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elpiscience Biopharma Ltd filed Critical Elpiscience Biopharma Ltd
Publication of JP2024531900A publication Critical patent/JP2024531900A/ja
Publication of JP2024531900A5 publication Critical patent/JP2024531900A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024505469A 2021-07-28 2022-07-28 新規の抗ｓｉｒｐａ抗体 Pending JP2024531900A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/109041 2021-07-28
CN2021109041 2021-07-28
CN2022104562 2022-07-08
CNPCT/CN2022/104562 2022-07-08
PCT/US2022/074286 WO2023010100A1 (en) 2021-07-28 2022-07-28 Novel anti-sirpa antibodies

Publications (2)

Publication Number Publication Date
JP2024531900A true JP2024531900A (ja) 2024-09-03
JP2024531900A5 JP2024531900A5 (enExample) 2025-08-04

Family

ID=85087323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505469A Pending JP2024531900A (ja) 2021-07-28 2022-07-28 新規の抗ｓｉｒｐａ抗体

Country Status (9)

Country Link
US (1) US20250270315A1 (enExample)
EP (1) EP4377358A4 (enExample)
JP (1) JP2024531900A (enExample)
KR (1) KR20240039006A (enExample)
CN (1) CN118076638A (enExample)
AU (1) AU2022317822A1 (enExample)
CA (1) CA3227854A1 (enExample)
TW (1) TW202313699A (enExample)
WO (1) WO2023010100A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153193A1 (en) * 2023-01-18 2024-07-25 Elpiscience (Suzhou) Biopharma, Ltd. Bi-specific molecules targeting sirpa and claudin 18.2
CN121712797A (zh) * 2023-04-27 2026-03-20 礼新医药科技(上海)有限公司 靶向SIRPα和Claudin 18.2的联合治疗
KR20260119373A (ko) * 2023-12-26 2026-07-31 상하이 홍쳉 바이오파머수티컬 코., 엘티디. 항-dll3 항체 또는 그의 항원 결합 단편 및 그 용도
KR20250164033A (ko) * 2024-05-14 2025-11-24 주식회사 지놈앤컴퍼니 항-bcam 항체 및 이의 컨쥬게이트

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013170A1 (ja) * 2018-07-10 2020-01-16 国立大学法人神戸大学 抗ＳＩＲＰα抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925931A (zh) * 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
US20210347908A1 (en) * 2019-08-20 2021-11-11 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
EP4081548A4 (en) * 2019-12-24 2024-07-24 LaNova Medicines Limited Anti-sirp? monoclonal antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020013170A1 (ja) * 2018-07-10 2020-01-16 国立大学法人神戸大学 抗ＳＩＲＰα抗体

Also Published As

Publication number Publication date
AU2022317822A1 (en) 2024-02-22
KR20240039006A (ko) 2024-03-26
EP4377358A4 (en) 2025-12-17
WO2023010100A1 (en) 2023-02-02
CA3227854A1 (en) 2023-02-02
CN118076638A (zh) 2024-05-24
EP4377358A1 (en) 2024-06-05
US20250270315A1 (en) 2025-08-28
TW202313699A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
AU2020286284B2 (en) Novel anti-CD39 antibodies
CN112867507B (zh) 新型抗sirpa抗体
ES2801873T3 (es) Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos
US20250270315A1 (en) Novel anti-sirpa antibodies
JPWO2018117237A1 (ja) 抗ｃｄ３抗体及び該抗体を含む分子
WO2024131962A1 (zh) 新型抗gprc5d抗体
TW202417494A (zh) 新穎抗ｌｉｌｒｂ４抗體及其用途
TW202304997A (zh) 新型抗ｃｄ４抗體
US20210115138A1 (en) Novel bispecific pd-1/lag-3 antibody molecules
WO2024175030A1 (zh) 抗Nectin-4抗体和包含其的多特异性抗体
KR20230079397A (ko) 신규 항-클라우딘18 항체
CN115558024A (zh) 抗b7-h3单克隆抗体及其用途
US20240336686A1 (en) Novel multi-specific molecules
US20250066510A1 (en) Gucy2c antibodies and uses thereof
CN116120461B (zh) 新型抗药抗体以及其用途
HK40106257A (zh) 新型抗sirpa抗体
TW202602939A (zh) 一種多特異性抗體t細胞銜接器
HK40045149A (en) Novel anti-sirpa antibodies
WO2025209594A1 (zh) 一种抗gucy2c抗体及其多特异性抗体的用途
TW202542184A (zh) 與ｃｄ３及ｌｉｌｒｂ４結合之新穎抗體及其用途
TW202334218A (zh) 新型抗ｌａｇ３抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260519